Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle
New Rapid Infusion Formulation Bolsters Originator
Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).
You may also be interested in...
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.